Spark Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Spark Therapeutics, Inc.
Otsuka steps into the ocular gene therapy field through a technology licensing deal worth up to $1.5bn with ShapeTX, which in turn further expands the US firm's global reach following a $3bn collaboration with Roche.
Six new drugs including Luxturna will be price-listed in Japan on 30 August, with the Novartis gene therapy set to become the second-most expensive therapeutic product in the country. Behind another round of market expansion-related price cuts for selected drugs, discussions on possible changes to the repricing system are ongoing.
The French non-profit, whose IP is incorporated in Zolgensma, is taking its Crigler-Najjar gene therapy into a pivotal study on its own for now. It hopes to be ready for an EU filing in two years.
The long-talked about wave of gene therapy approvals is beginning to reveal itself.
- Drug Delivery
- Site Specific
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Genable Technologies Limited
- Roche Holding AG (RHHBY)
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.